ASLAN Pharmaceuticals Ltd ADR (NASDAQ: ASLN) closed the day trading at $0.65 up 0.05% from the previous closing price of $0.65. In other words, the price has increased by $+0.0003 from its previous closing price. On the day, 630273 shares were traded.
Ratios:
For a better understanding of ASLN, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.11 and its Current Ratio is at 2.11.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on July 09, 2021, initiated with a Buy rating and assigned the stock a target price of $8.
On January 14, 2019, H.C. Wainwright reiterated its Buy rating and also upped its target price recommendation from $12 to $8.50.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ASLN now has a Market Capitalization of 11.51M and an Enterprise Value of 9.02M. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.92. Its current Enterprise Value per Revenue stands at 0.75 whereas that against EBITDA is -0.22.
Stock Price History:
Over the past 52 weeks, ASLN has reached a high of $4.69, while it has fallen to a 52-week low of $0.39. The 50-Day Moving Average of the stock is 0.6318, while the 200-Day Moving Average is calculated to be 1.5215.
Shares Statistics:
Over the past 3-months, ASLN traded about 1.02M shares per day on average, while over the past 10 days, ASLN traded about 5.07M shares per day. A total of 16.67M shares are outstanding, with a floating share count of 16.09M. Insiders hold about 3.48% of the company’s shares, while institutions hold 20.89% stake in the company. Shares short for ASLN as of Feb 29, 2024 were 19.33k with a Short Ratio of 0.02, compared to 58.67k on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 0.12% and a Short% of Float of 0.12%.
Earnings Estimates
Current recommendations for the stock of the company come from 1 analysts. On average, analysts expect EPS of -$0.65 for the current quarter, with a high estimate of -$0.65 and a low estimate of -$0.65, while EPS last year was -$1.04. The consensus estimate for the next quarter is -$0.6, with high estimates of -$0.6 and low estimates of -$0.6.
Analysts are recommending an EPS of between -$2.61 and -$2.61 for the fiscal current year, implying an average EPS of -$2.61. EPS for the following year is -$3.48, with 1 analysts recommending between -$3.48 and -$3.48.
